摘要:

One hundred ten patients were randomized to receive one of the following antibiotic combinations: aztreonam + clindamycin, tobramycin + clindamycin, or amikacin + mezlocillin for the treatment of lower respiratory tract infections (LRTI) caused by gram-negative bacilli. Of the 68 patients who received aztreonam + clindamycin, 60 were clinically evaluable and 50 were bacteriologically evaluable. Of the 60 clinically evaluable patients, 54 were cured and 5 were treatment failures or died during the study period. Of the 50 bacteriologically evaluable patients, 46 were cured and 3 failed to respond to therapy. Of the 26 clinically evaluable patients in the tobramycin + clindamycin group, 22 were cured and 4 either failed to respond or died during the study period. Of 18 bacteriologically evaluable patients in this group, 16 were cured and 2 failed to respond. In the amikacin + mezlocillin group, 14 of the 15 clinically and bacteriologically evaluable patients were cured, and 1 failed to respond. The most commonly isolated pathogens were Klebsiella pneumoniae, Escherichia coli, and Pseudomo-nasaeruginosa. The very few adverse drug reactions that were seen were transient and comparable in all three groups except for renal function parameters, which deteriorated in 6–8% of patients receiving the aminoglycoside combination. All three antibiotic combinations were similar in effectiveness and safet

ISSN:0009-3157    

DOI:10.1159/000238726

出版商:S. Karger AG    

年代:1989

数据来源: Karger

摘要:

Aztreonam was administered to 25 neonates (16 term, 9 premature) with clinically and bacteriologically proved gram-negative infections. Ten patients had meningitis, 9 had septicemia and 6 had urinary tract infections. Patients were between 1 and 28 days of age. Aztreonam was administered intravenously in doses ranging from 40 to 120 mg/kg/day for 10–30 days, depending on the causative organism. All CSF, blood and urine cultures were sterile 48 h after drug treatment had begun. There was no incidence of bacteriologic relapse. Body temperature returned to normal in 96% of patients within 3–4 days of therapy. Aztreonam was well tolerated. One infant experienced nausea and vomiting, but no patient was withdrawn from therapy due to adverse reacti

ISSN:0009-3157    

DOI:10.1159/000238727

出版商:S. Karger AG    

年代:1989

数据来源: Karger

ISSN:0009-3157    

DOI:10.1159/000238728

出版商:S. Karger AG    

年代:1989

数据来源: Karger

ISSN:0009-3157    

DOI:10.1159/000238729

出版商:S. Karger AG    

年代:1989

数据来源: Karger

ISSN:0009-3157    

DOI:10.1159/000238715

出版商:S. Karger AG    

年代:1989

数据来源: Karger